| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
The primary targets of Olvanil include TRPV1 (transient receptor potential vanilloid type 1), CB1, and CB2 receptors. It acts as a potent agonist of TRPV1 with an EC50 of 0.7 nM. It also acts as a "mixed" activator of CB1 (Ki = 1.6 µM) and CB2 (Ki = 15 µM) receptors. Its effects on pain and inflammation are mediated through these receptors.
|
|---|---|
| ln Vitro |
Olvanil has an IC50 value of 5.5 μM on the growth of C6 glioma cells[2].
In vitro, Olvanil is a potent TRPV1 agonist with an EC50 of 0.7 nM. It affects C6 glioma cell proliferation with an IC50 of 5.5 µM. It also interacts with the anandamide transporter. Its activity is typically measured using calcium imaging or electrophysiological techniques in cells expressing TRPV1. |
| ln Vivo |
An analog of capsaicin, olvanil agonistically interacts with vanillic acid receptors. Olvanil may have affects similar to anxiety. The percentages of open-arm entries within 5 minutes were 25±10.1, 19.3±7.1, 14.9±5.9, and 0±0 for Olvanil dosages of 0, 0.2, 1.0, and 5.0 mg/kg, in that order [3].
In vivo, Olvanil is a capsaicin analog with analgesic activity. It has been studied for its potential therapeutic applications in pain management, cancer treatment, and inflammation. It has anti-inflammatory and anti-cancer properties. |
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Olvanil involve radioligand binding studies using cell membranes expressing TRPV1, CB1, or CB2 receptors. Competitive binding assays are performed using selective radiolabeled ligands to determine the compound's affinity (Ki) for these receptors. Functional assays (e.g., calcium influx) are used to assess its agonist activity at TRPV1.
|
| Cell Assay |
In vitro cellular assays for Olvanil are conducted in cells expressing TRPV1 (e.g., sensory neurons) or cancer cell lines such as C6 glioma cells. Cells are treated with the compound, and calcium influx is measured using fluorescent indicators to assess TRPV1 activation. Cell proliferation is measured using MTT or similar assays.
|
| Animal Protocol |
Animal/Disease Models: SD (SD (Sprague-Dawley)) rats [3] weighing approximately 200 g Doses: 0, 0.2, 1.0 and 5.0 mg/kg
Route of Administration: intraperitoneal (ip) injection 30 minutes before behavioral testing Experimental Results: Percent arm time at 5 minutes was 12.9 ± 8.1 for the 0 mg/kg dose, 8.9 ± 4.2 for the 0.2 mg/kg dose, 15.2 ± 7.9 for the 1 mg/kg dose, and 0 ± 0 for the 5 mg/kg dose. The mean number of closed arm entries at 5 minutes was 1.7±0.3, 3.3±0.8, 2.7±0.3 and 0.25±0.1 for doses of 0, 0.2, 1 and 5 mg/kg, respectively. In vivo animal studies for Olvanil are conducted in animal models of pain and inflammation. Animals are administered the compound orally, intraperitoneally, or topically, and its analgesic effects are assessed using standard pain tests such as the hot plate test, tail flick test, or formalin test. Its anti-inflammatory and anticancer activities are evaluated in relevant models. |
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Olvanil indicate it has a molecular weight of 417.62 and a molecular formula of C26H43NO3. It is soluble in DMSO (up to 100 mM) and ethanol (up to 25 mM). The compound is typically stored as a powder at appropriate conditions. Its bioavailability and other PK parameters would be determined in preclinical studies.
|
| Toxicity/Toxicokinetics |
Toxicological information for Olvanil is limited to its use as a research chemical. As a TRPV1 agonist, it may cause pain and irritation at high concentrations. Comprehensive toxicology studies would be required for clinical development, including assessments of its effects on pain, inflammation, and cancer.
|
| References |
|
| Additional Infomation |
N-Vanillyl Oleamide belongs to the methoxybenzene class of compounds and also to the phenolic class of compounds.
Olvanil is a potent TRPV1 agonist with analgesic and anti-inflammatory properties. It is also known as N-Vanillyloleamide or NE-19550. It is 10 times more potent than capsaicin as a TRPV1 agonist. It is available from research chemical suppliers for preclinical studies. It is not approved for clinical use. |
| Molecular Formula |
C26H43NO3
|
|---|---|
| Molecular Weight |
417.63
|
| Exact Mass |
417.324
|
| CAS # |
58493-49-5
|
| PubChem CID |
5311093
|
| Appearance |
White to off-white solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
596.1±50.0 °C at 760 mmHg
|
| Flash Point |
314.3±30.1 °C
|
| Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
| Index of Refraction |
1.509
|
| LogP |
7.69
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
18
|
| Heavy Atom Count |
30
|
| Complexity |
438
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCC/C=C\CCCCCCCC(=O)NCC1=CC(=C(C=C1)O)OC
|
| InChi Key |
OPZKBPQVWDSATI-KHPPLWFESA-N
|
| InChi Code |
InChI=1S/C26H43NO3/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-26(29)27-22-23-19-20-24(28)25(21-23)30-2/h10-11,19-21,28H,3-9,12-18,22H2,1-2H3,(H,27,29)/b11-10-
|
| Chemical Name |
(Z)-N-[(4-hydroxy-3-methoxyphenyl)methyl]octadec-9-enamide
|
| Synonyms |
Olvanilo Vanillyloleamide Olvanil
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~239.45 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3945 mL | 11.9723 mL | 23.9446 mL | |
| 5 mM | 0.4789 mL | 2.3945 mL | 4.7889 mL | |
| 10 mM | 0.2394 mL | 1.1972 mL | 2.3945 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
